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Abstract 
PURPOSE 
To identify predictors for discontinuation of adjuvant hormone therapy in breast cancer 
patients. 
PATIENTS AND METHODS 
We conducted a record-linkage study based on data from Stockholm-Gotland Breast Cancer 
Register, Swedish Prescribed Drug Register, and self-reported questionnaire. Women 
diagnosed with breast cancer between 2005 and 2008 in Stockholm, Sweden, were 
prospectively followed for five years until 2013, starting from their first prescription of 
tamoxifen or aromatase inhibitors (N=3 395).  
RESULTS 
Family history of ovarian cancer (HR, 1.55; 95% CI: 1.19-2.02), younger (<40 years; HR, 
1.39; 95% CI: 1.08-1.78) and older (≥65 years; HR, 1.15; 95% CI: 1.03-1.28) age, higher 
Charlson comorbidity index (≥2 vs 0; HR, 1.35; 95% CI: 1.03-1.76), use of analgesics (HR, 
1.33; 95% CI: 1.16-1.52), hypnotics/sedatives (HR, 1.24; 95% CI: 1.07-1.43), gastrointestinal 
drugs (HR, 1.25; 95% CI: 1.08-1.43), and hormone replacement therapy (HR, 1.27; 95% CI: 
1.08-1.49), were identified as baseline predictors for hormonal treatment discontinuation. Use 
of analgesics (HR, 1.22; 95% CI: 1.08-1.37), hypnotics/sedatives (HR, 1.21; 95% CI: 1.07-
1.37), antidepressants (HR, 1.22; 95% CI: 1.06-1.40), or gastrointestinal drugs (HR, 1.27; 95% 
CI: 1.13-1.43), and switching therapy between tamoxifen and aromatase inhibitors (HR, 1.50; 
95% CI: 1.23-1.83), during the first year of hormonal treatment were associated with 
increased risk of discontinuation during the following four years.  
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CONCLUSION 
Predictors identified in our study can be used in developing targeted intervention to prevent 
adjuvant hormone therapy discontinuation and subsequently to improve breast cancer 
outcomes. 
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INTRODUCTION 
Adjuvant hormone therapy, such as tamoxifen and aromatase inhibitors (AIs), lowers the 
risk of breast cancer recurrence by 41% and cancer-specific mortality by 31%.
1
 However, 
despite the survival benefit of adjuvant hormone therapy,
2
 a substantial proportion of breast 
cancer patients – ranging from 31 to 73% – discontinue their treatment3-6 and therefore 
diminished therapeutic effects.
4,7-10
 
Treatment-related side effects, including pain, depression, sleep disorders, and 
gastrointestinal reaction such as nausea and vomiting, are known as the major reason for 
discontinuing adjuvant hormone therapy.
6,11,12
 Clinicians do their best to support patients by 
prescribing symptom-relieving drugs. However, whether a prescription of a symptom-
relieving drug is still associated with future discontinuation remains unknown.  
Apart from treatment-related side effects, several factors have been suggested to be 
associated with discontinuation of adjuvant hormone therapy, including younger and older 
age, higher prescription co-payment, higher Charlson comorbidity index, and switching 
therapy between tamoxifen and AIs.
3,6,13,14
 However, previous studies usually suffer from 
small sample size, short follow-up time, and selected study population (such as using hospital 
based samples or including only low income women); and contradictory results for some 
predictors have also been reported.
5,12-21
 
By linking data from several Swedish registers and a large population-based cohort, the 
present study was conducted to identify predictors for discontinuation of adjuvant hormone 
therapy in breast cancer patients. Our first aim was to identify baseline predictors for 
discontinuation, including use of hormone replacement therapy (HRT), use of symptom-
relieving drugs prior to diagnosis, lifestyle factors, reproductive factors, socio-economic 
status, family history of breast or ovarian cancer, comorbidities and tumor characteristics. Our 
second aim was to identify early-treatment-stage predictors for long-term discontinuation by 
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investigating whether use of symptom-relieving drugs and switching therapy between 
tamoxifen and AIs, within the first year of treatment could be used to predict the 
discontinuation of adjuvant hormone therapy in the following four years. 
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PATIENTS AND METHODS 
Data sources and patients 
Swedish Registers 
The Stockholm-Gotland Breast Cancer Register contains detailed information on all 
patients diagnosed with breast cancer in Stockholm-Gotland region of Sweden since 1976, 
including data on pre-surgical diagnostics, tumor characteristics, therapy of the breast cancer, 
and post-treatment follow-up.
22
 
The Swedish Prescribed Drug Register contains information on all prescribed medicines 
dispensed by Swedish pharmacies since July 1, 2005, including dates of prescription and 
dispense, number of defined daily dose, and classification of drugs according to the 
Anatomical Therapeutic Chemical (ATC) Classification System. This register is reported to 
be nationwide complete, with <0.3% of data entries with missing Personal Identification 
Numbers.
23
 
Using the individually unique Personal Identification Numbers,
24
 we linked the 
Stockholm-Gotland Breast Cancer Register to the Swedish Prescribed Drug Register. 
Through this linkage, we identified 3 470 patients diagnosed with breast cancer between 2005 
and 2008 in Stockholm, Sweden, who initiated adjuvant hormone therapy with at least one 
prescription of tamoxifen (ATC codes L02BA01) or AIs (ATC codes L02BG). Furthermore, 
we excluded 45 patients with distant metastasis at diagnosis and 30 patients with ER-negative 
breast cancer, leaving a total of 3 395 breast cancer patients for the final analysis. (Figure 1) 
Self-reported Questionnaire Survey 
During 2009-2010, 1 997 (59 %) of the 3 395 breast cancer patients answered a 
structured questionnaire in order to identify prognostic factors for breast cancer.
25,26
 All 
subjects participated in the questionnaire survey provided written informed consent.  
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Discontinuation of adjuvant hormone therapy 
Information on prescription and dispense of tamoxifen and AIs was obtained from the 
Swedish Prescribed Drug Register. We defined discontinuation of adjuvant hormone therapy 
as having any interval between two consecutive dispenses exceeding 180 days during the 
follow-up. Since a maximum of 3-month supply of prescription drugs can be dispensed in 
Sweden, a gap of 180 days indicates that at least two dispenses have been missed, thus 
resulting in a shortage of the drug.
27
 
Patients were followed from the first prescription of tamoxifen or AIs, until treatment 
discontinuation, death, local recurrence, distant metastasis, contralateral cancer, endometrial 
cancer, venous thromboembolism, end of study period (31 August 2013), or completion of 
five-year treatment, whichever occurred first (Appendix Table A1, online only). Time to 
discontinuation was defined as the time interval between the first and last prescriptions plus 
the days of supply from the last prescription. Information on death, local recurrence, distant 
metastasis, and contralateral cancer was retrieved from the Stockholm-Gotland Breast Cancer 
Register. Information on endometrial cancer (ICD-10: C541) were retrieved from Swedish 
Cancer Register
28
 and information on venous thromboembolism (ICD-10: I260, I269, I801-3, 
I808-9, I822-3, I828-9) was retrieved from the Swedish Inpatient Register.
29
 
Baseline predictors of discontinuation  
Information on baseline use of symptom relieving drugs and HRT was retrieved from the 
Swedish Prescribed Drug Register. Baseline use of symptom-relieving drugs, including 
analgesics (ATC codes N02), hypnotics/sedatives (ATC codes N05C), antidepressants (ATC 
codes N06A), and gastrointestinal drugs (ATC codes A02, A03, A04, A06, A07), was defined 
as filling at least one prescription of corresponding drugs one year before diagnosis of breast 
cancer (Appendix Table A2, online only). Pre-diagnosis HRT was defined as filling at least 
one prescription of estrogen/progesterone (ATC codes G03C, G03D, G03F) for systematic 
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use one year before breast cancer diagnosis, excluding local use such as patch and vaginal 
cream.  
Information on age at diagnosis, menopausal status at diagnosis, primary tumor size, 
lymph node metastases, progesterone receptor status, radiotherapy, and chemotherapy was 
retrieved from the Stockholm-Gotland Breast Cancer Register. 
Information on comorbidities used to calculate the Charlson Comorbidity Index was 
retrieved from Swedish Inpatient Register, including all main diagnoses for hospital 
admissions since 1987 but before breast cancer diagnosis.
30
  
Information on education, cigarette smoking, self-reported HRT at diagnosis, body mass 
index (BMI), and family history of breast or ovarian cancer was retrieved from the self-
reported questionnaire. 
Early-treatment-stage predictors of discontinuation 
Early-treatment-stage use of symptom-relieving drugs was defined as filling at least one 
prescription of the symptom-relieving drugs during the first year of adjuvant hormone therapy. 
Switching therapy was defined as switching from tamoxifen to AIs or vice versa during the 
first year of adjuvant hormone therapy. 
Data analysis 
Cox regression analysis was used to identify baseline predictors for discontinuation of 
adjuvant hormone therapy. The Schoenfeld residual test was used to check the proportionality 
assumption of the Cox regression. A violation of the assumption was suggested for pre-
diagnosis HRT. The time-dependent hazard ratios (HRs) for pre-diagnosis HRT were 
therefore estimated using flexible parametric survival models.
31
 
To identify early-treatment-stage predictors for long-term discontinuation, we used Cox 
regressions analysis to investigate whether use of analgesics, hypnotics/sedatives, 
antidepressants, and gastrointestinal drugs, as well as switching therapy between tamoxifen 
10 
 
and AIs, within the first year of treatment could be used to predict the discontinuation of 
adjuvant hormone therapy in the coming four years. Patients discontinued or censored already 
during the first year of follow-up were excluded in these analyses. Specifically, we used 
Kaplan-Meier failure time plot to illustrate the cumulative probability of treatment 
discontinuation during the following four years according to the number (0, 1-2, 3-4) of early-
treatment-stage symptom-relieving drugs.  
Sensitivity analyses were conducted to assess the robustness of our findings: we restricted 
our analyses to women without any prescription of symptom-relieving drugs during the year 
prior to breast cancer diagnosis; we redefined the use of symptom-relieving drugs as filling at 
least two corresponding drugs; we re-analyzed our data using competing risk regression;
32
 and 
we stratified our analysis by type of adjuvant hormone therapy. 
All analyses were conducted using SAS software (version 9.4; SAS Institute Inc, Cary, 
NC, USA) or Stata software (version 13.0; Stata corporation, college station, TX), at a two-
tailed alpha level of 0.05. The study was approved by the Regional Ethical Review Board in 
Stockholm, Sweden.  
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RESULTS 
Subject characteristics 
Table 1 presents baseline characteristics of breast cancer patients. Most patients were 
aged 40-64 years at the time of diagnosis, with 35% aged ≥65 years, and only 4% aged <40 
years. 
Discontinuation of adjuvant hormone therapy 
Discontinuation of adjuvant hormone therapy increased in a linear fashion during the 
follow-up: by the end of year one, 14% of the patients discontinued the treatment; by the end 
of year three, 36%; by the end of year five, which was the recommended duration of adjuvant 
hormone therapy at the time of the study, the rate of discontinuation approached 54%.  
Baseline predictors for discontinuation 
Use of analgesics, hypnotics/sedatives, antidepressants, or gastrointestinal drugs one year 
before breast cancer diagnosis was all associated with higher discontinuation of adjuvant 
hormone therapy in the univariable models. In the multivariable model, use of analgesics (HR, 
1.33; 95% CI, 1.16 to 1.52), hypnotics/sedatives (HR, 1.24; 95% CI, 1.07 to 1.43), and 
gastrointestinal drugs (HR, 1.25; 95% CI, 1.08 to 1.43) remained statistically significant 
(Table 1).  
Use of HRT one year before diagnosis of breast cancer was associated with higher 
discontinuation of adjuvant hormone therapy during the first year but not afterwards (Figure 
2). Similar associations were also observed for self-reported HRT, with significantly higher 
HRs for the first year of follow-up (current users: HR=1.78 [95% CI, 1.14 to 2.76]; past users: 
HR=1.31 [95% CI, 0.95 to 1.82]) but not afterwards. 
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Other baseline predictors for discontinuation of adjuvant hormone therapy included 
younger and older age at cancer diagnosis, higher Charlson comorbidity index, and family 
history of ovarian cancer (Table 1).  
Early-treatment-stage (first-year) predictors for long-term discontinuation 
Use of symptom-relieving drugs within the first year of follow-up was associated with 
higher discontinuation of adjuvant hormone therapy in the following four years (Table 2). 
Furthermore, the rate of discontinuation of adjuvant hormone therapy in the following four 
years increased significantly with the increasing number of symptom-relieving drugs used 
during the first year of treatment. The discontinuation rate was 37%, 50%, and 62% for 
patients who used 0, 1-2, and 3-4 drugs, respectively (Figure 3). Patients who switched 
therapy from tamoxifen to AIs or vice versa during the first year of follow-up were also at 
increased risk of discontinuation in the following four years (HR, 1.50; 95% CI, 1.23 to 1.83). 
Sensitivity analyses 
Restricting the analysis to women without any prescription of symptom-relieving drugs 
during the year before breast cancer diagnosis (Appendix Table A3, online only), redefining 
the use of symptom-relieving drugs as filling at least two corresponding drugs (Appendix 
Table A4 and Table A5, online only), and re-analyzing our data using competing risk 
regression (Appendix Table A6 and Table A7, online only) provided similar results as in the 
main analysis. Stratified analyses by type of adjuvant hormone therapy also yielded 
comparable results, with higher HRs for pre-diagnosis HRT during the first year of follow-up 
(Tamoxifen alone: HR=2.10 [95% CI, 1.40 to 3.14]; AIs alone: HR=1.96 [95% CI, 1.14 to 
3.37] ) but not the following years. Higher HRs were also found for symptom-relieving drugs 
in the stratified analyses (Appendix Table A8, online only).  
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DISCUSSION 
In this population-based cohort of 3 395 breast cancer patients, over half of the patients 
discontinued adjuvant hormone therapy during the 5-year follow-up. Use of medications for 
pain, sleep disorders, depression, and gastrointestinal disorders both before diagnosis and 
during the first year of treatment was identified as predictors for discontinuation of adjuvant 
hormone therapy. Pre-diagnosis HRT was found to be associated with discontinuation of 
adjuvant hormone therapy in the first year of treatment, but not afterwards. Other predictors 
for discontinuation included younger and older age at cancer diagnosis, positive family 
history of ovarian cancer, higher comorbidities, and switching therapy between tamoxifen and 
AIs during the first year of treatment. 
Women on adjuvant hormone therapy for breast cancer are generally expected to be 
highly motivated since they are facing a life-threating disease, the adjuvant therapy is 
effective, easy to use, and generally well tolerated. However, in our unselected population, 
over half of the breast cancer patients discontinued their treatment during a 5-year period. 
This rate corroborates with previous studies that have reported a 5-year discontinuation rate of 
31 to 73%.
3
 Discontinuation of adjuvant hormone therapy is likely to result in significantly 
worse outcomes for breast cancer patients,
4
 thus represents an important issue that needs to be 
addressed. 
A further problem is that women who experienced treatment-related side effects may be 
the ones that benefit adjuvant therapy since side effects could be a proxy for therapy 
response.
33
 Although still somewhat controversial,
34
 patients who experiencing more 
pronounced treatment-related symptoms have been shown to have a lower rate of breast 
cancer recurrence than those not reporting symptoms.
33,35
 Unfortunately, higher 
discontinuation was found among users of symptom-relieving drugs in our study, suggesting 
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that patients who were potentially more likely to benefit from the treatment were more often 
discontinuing the adjuvant hormone therapy.  
Of the patients discontinuing their therapy, most women (74%) stopped taking the drug 
after the first year of treatment. This gives the responsible clinician an opportunity to identify 
patients at higher risk of stop taking the prescribed medication. Consequently, the first year of 
treatment may serve as a good opportunity for potential interventions. Furthermore, it seems 
for instance obvious that the symptom-relieving drugs used in the current population did not 
stop the majority of patients from discontinuation, indicating that a therapy shift or a dose 
adjustment of the symptom–relieving drugs is warranted.  
In addition to post-diagnosis drugs, pre-diagnosis symptom-relieving drugs were also 
found to be associated with early discontinuation of adjuvant hormone therapy in our study. 
This result is expected given that psychological problems have been cited as an important 
determinant for treatment compliance in oncology patients.
36
 Another study by Barron et al. 
reported a significant association between pre-diagnosis antidepressants and discontinuation 
of tamoxifen treatment, but not Benzodiazepine and antipsychotic drugs.
19
 That study, 
however, over-sampled the elderly and the socioeconomically disadvantaged groups, and used 
only data from a pharmacy register. 
Pre-diagnosis HRT was associated with early discontinuation of adjuvant hormone 
therapy, which may be due to the intolerable menopause-like symptoms caused by both 
stopping HRT and initiation of adjuvant hormone therapy. Importantly, the impact of HRT 
appears to be specific for early discontinuation as the hazard ratios declined clearly over time, 
suggesting that early and late discontinuation of adjuvant hormone therapy may have different 
underlying causes. Therefore, different strategy should be considered to prevent early and late 
discontinuation of adjuvant hormone therapy. 
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In line with previous studies, discontinuation rates were higher among the younger (<40 
years) and older (≥65 years) patients.37 That younger patients are particularly likely to stop 
taking their medications is of concern as younger women have a worse prognosis,
38
 
particularly so if they discontinue treatment.
39
 Furthermore, consistent with previous 
studies,
27
  higher discontinuation of adjuvant hormone therapy was found among patients who 
switched therapy during the first year of treatment, potentially as an indicator of greater side 
effects associated with the original therapy.
40
  
Our results on family history of ovarian cancer may be due to chance alone, although it is 
possible that having experienced another lethal cancer (e.g., ovarian cancer) in the family 
might have made the breast cancer patients less confident in cancer treatment in general. 
The major strength of our study is that we pooled individual data from several different 
sources, namely the Stockholm-Gotland Breast Cancer Register, the Swedish Prescribed Drug 
Register, and the self-reported questionnaire data. In contrast, previous studies were either 
purely register-based
13,18,27
 or questionnaire-based.
12,17
 The similar findings of HRT, either 
with data obtained from the Prescribed Drug Register or from self-reported questionnaire, 
further stress the robustness of the different sources of information used in the present study. 
Furthermore, the Prescribed Drug Register provides accurate and objective estimates of 
medication use in the entire population of Sweden since July 2005 and has been widely used 
to measure medication compliance in other studies.
27
 Other strengths of the present study 
include the population-based design and large sample size.  
A few limitations should be addressed. First, prescription refill does not necessarily 
guarantee a patient actually consumes the prescribed medication. Hence, our study might have 
underestimated the prevalence of treatment discontinuation. Second, because only dispensed 
medications are recorded in the Prescribed Drug Register,
23
 our study lack information on 
patients who were prescribed with tamoxifen or AIs but never withdraw them from the 
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pharmacies. Third, potential misclassification of the use of analgesics and gastrointestinal 
drugs is possible because the Swedish Prescribed Drug Register does not contain information 
on purchases of over-the-counter drugs.
23
 However, given the fact that majority of the studied 
symptom-relieving drugs are prescribed medications, and small dose, long term use of 
analgesics is also prescribed, we believe this misclassification is likely to be small. Fourth, 
only 59% of the study participants responded to the questionnaire survey, which might have 
led to some uncertainty in the representativeness of the questionnaire-based information (e.g. 
family history of ovarian cancer). Fifth, given that we tested multiple predictors in the present 
study, false positive finding due to multiple testing to some extent remains possible. Finally, 
in addition to adjuvant hormone therapy, the use of symptom-relieving drugs may also be due 
to reasons other than the side effect of hormonal treatment, including for example severe 
psychological distress experienced after receiving breast cancer diagnosis. However, 
regardless of the underlying reasons for the use of these drugs, our conclusion that the use of 
symptom-relieving drugs in the first year can be used to predict the discontinuation of 
adjuvant hormone therapy in the following four years still holds. 
In summary, during the first five years following treatment initiation more than 50% of 
the breast cancer patients discontinued their adjuvant hormone therapy in this population-
based Swedish cohort. Predictors of discontinuation included family history of ovarian cancer, 
age at diagnosis, higher comorbidities, switching therapy between tamoxifen and aromatase 
inhibitors, use of analgesics, hypnotics/sedatives, antidepressants, and gastrointestinal drugs. 
Interestingly, pre-diagnosis HRT is associated with early discontinuation, but not later 
discontinuation of adjuvant hormone therapy. It thus seems possible for the treating physician 
to identify factors that indicates which patients will stop using adjuvant therapy. Future 
interventions, including side effect management, patient education, and frequent monitoring 
17 
 
of symptom-relieving drugs, may help to improve treatment continuation and subsequently 
improve breast cancer outcomes.  
18 
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Figure legend 
Fig 1. Flow chart of study participants. 
 
Fig 2. Time-dependent hazard ratios (HRs) for discontinuation of adjuvant hormone therapy. 
HRs estimated from flexible parametric survival models, adjusting for age at diagnosis, 
family history of ovarian cancer, Charlson comorbidity index, pre-diagnosis use of analgesics, 
hypnotics/sedatives, and gastrointestinal drugs. Curves cut off at 90 days from initiation of 
adjuvant hormone therapy because of sparse data. Pre-diagnosis hormone replacement therapy 
is defined as filling at least one prescription of estrogen/progesterone for systematic use one 
year before diagnosis of breast cancer. Premenopausal women (N=863) and women 
diagnosed before July 2006 (N=725) were excluded from this analysis.  
 
Fig 3. Discontinuation of adjuvant hormone therapy according to number of post-diagnosis 
symptom-relieving drugs used in the first year of follow-up. 
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Tables 
Table 1.  Baseline characteristics and their relation with discontinuation of adjuvant hormone 
therapy among 3 395 breast cancer patients in Stockholm, Sweden, 2005-2013. 
 
Characteristics 
No. of patients  Time to 25% 
Discontinuation, 
years (95%CI)
 *
 
 Hazard ratios (95% CI) 
 
Total 
Disconti- 
nuers(%) 
 
Univariable 
 
Multivariable
†
 
Register data        
Age at diagnosis, yrs        
        <40  129 76(58.9)  1.6(1.4-2.2)  1.30(1.03-1.64) 1.39(1.08-1.78) 
        40-64  2083 1029(49.4)  2.1(1.9-2.2)  1.00(reference) 1.00(reference) 
        ≥65 1183 638(53.9)  1.5(1.4-1.8)  1.21(1.10-1.34) 1.15(1.03-1.28) 
Menopausal status        
        Pre-menopause 863 426(49.4)  2.0(1.6-2.2)  1.00(reference) 1.00 
        Post-menopause 2378 1250(52.6)  1.8(1.6-1.9)  1.12(1.00-1.25) 1.05(0.86-1.30) 
        Unknown 154 67(43.5)  3.1(2.1-3.8)  ─ ─ 
Charlson comorbidity index        
        0 3096 1589(51.3)  1.9(1.8-2.1)  1.00(reference) 1.00(reference) 
        1 195 96(49.2)  1.7(1.1-2.2)  1.03(0.84-1.27) 0.89(0.72-1.10) 
        ≥2 104 58(55.8)  0.9(0.5-1.5)  1.47(1.13-1.91) 1.35(1.03-1.76) 
Primary tumor        
        Not palpable tumor 730 376(51.5)  1.7(1.5-2.0)  1.01(0.89-1.14) ─ 
        Tumor<20 mm 1498 793(52.9)  2.1(1.9-2.2)  1.00(reference) ─ 
        Tumor 21-50 mm 958 469(49.0)  1.8(1.5-2.1)  0.97(0.87-1.09) ─ 
        Tumor>50 mm 195 99(50.8)  1.3(1.1-1.9)  1.14(0.92-1.40) ─ 
        Unknown 14 6(42.9)  1.7(0.6-.)  ─ ─ 
Lymph node metastases        
        No 2961 1523(51.4)  1.9(1.7-2.0)  1.00(reference) ─ 
        Yes 422 214(50.7)  1.7(1.5-2.1)  1.08(0.93-1.24) ─ 
        Unknown 12 6(50.0)  1.0(0.3-2.7)  ─ ─ 
Progesterone receptor status        
        Positive 2592 1323(51.0)  1.9(1.8-2.1)  1.00(reference) ─ 
        Negative 707 367(51.9)  1.9(1.7-2.1)  1.05(0.94-1.18) ─ 
        Unknown 96 53(55.2)  0.9(0.5-1.1)  ─ ─ 
Radiotherapy        
        No 667 333(49.9)  2.0(1.7-2.2)  1.00(reference) ─ 
        Yes 2653 1367(51.5)  1.9(1.7-2.1)  1.02(0.91-1.15) ─ 
        Unknown 75 43(57.3)  0.7(0.5-1.3)  ─ ─ 
Chemotherapy        
        No 2346 1223(52.1)  1.8(1.6-2.0)  1.00(reference) ─ 
        Yes 957 469(49.0)  2.0(1.8-2.3)  0.92(0.83-1.02) ─ 
        Unknown 92 51(55.4)  1.1(0.5-1.5)  ─ ─ 
Pre-diagnosis  
symptom-relieving drugs
‡
 
       
        Analgesics        
                No 1914 908(47.4)  2.1(2.0-2.3)  1.00(reference) 1.00(reference) 
                Yes 519 312(60.1)  1.5(1.3-1.6)  1.51(1.33-1.72) 1.33(1.16-1.52) 
                Unknown 962 523(54.4)  1.7(1.4-2.0)  ─ ─ 
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Characteristics 
No. of patients  Time to 25% 
Discontinuation, 
years (95%CI)
 *
 
 Hazard ratios (95% CI) 
 
Total 
Disconti- 
nuers(%) 
 
Univariable 
 
Multivariable
†
 
        Hypnotics and sedatives        
                No 1966 942(47.9)  2.1(1.9-2.2)  1.00(reference) 1.00(reference) 
                Yes 467 278(59.5)  1.4(1.1-1.6)  1.44(1.26-1.65) 1.24(1.07-1.43) 
                Unknown 962 523(54.4)  1.7(1.4-2.0)  ─ ─ 
        Antidepressants        
                No 2112 1034(49.0)  2.0(1.8-2.1)  1.00(reference) 1.00(reference) 
                Yes 321 186(57.9)  1.7(1.4-2.1)  1.29(1.11-1.51) 1.09(0.92-1.28) 
                Unknown 962 523(54.4)  1.7(1.4-2.0)  ─ ─ 
        Gastrointestinal drugs        
                 No 1930 920(47.7)  2.1(1.9-2.2)  1.00(reference) 1.00(reference) 
                 Yes 503 300(59.6)  1.6(1.3-1.8)  1.43(1.26-1.63) 1.25(1.08-1.43) 
                 Unknown 962 523(54.4)  1.7(1.4-2.0)  ─ ─ 
Pre-diagnosis  HRT
‡
        
        No 1479 729(49.3)  2.0(1.8-2.2)  1.00(reference) 1.00(reference) 
        Yes 328 192(58.5)  1.4(1.0-1.7)  1.27(1.09-1.49) 1.27(1.08-1.49) 
        Unknown 1588 822(51.8)  1.9(1.6-2.1)  ─ ─ 
Questionnaire data        
Education, years        
        >12 818 385(47.1)  2.3(2.0-2.7)  1.00(reference) ─ 
        9-12 443 212(47.9)  2.1(1.8-2.4)  1.04(0.88-1.23) ─ 
        ≤9 266 141(53.0)  2.1(1.6-2.6)  1.17(0.96-1.41) ─ 
        Other 376 206(54.8)  1.9(1.5-2.2)  1.23(1.04-1.46) ─ 
        Unknown 1492 799(53.6)  1.6(1.4-1.7)  ─ ─ 
Cigarette smoking        
        Never 815 388(47.6)  2.2(2.1-2.5)  1.00(reference) ─ 
        Ever 1099 557(50.7)  2.0(1.8-2.2)  1.08(0.95-1.23) ─ 
        Unknown 1481 798(53.9)  1.5(1.4-1.7)  ─ ─ 
Body mass index (BMI)        
        BMI<25 kg/m
2
 986 483(49.0)  2.1(1.9-2.3)  1.00(reference) ─ 
        25≤BMI<30 kg/m2 691 346(50.1)  2.0(1.7-2.3)  1.02(0.89-1.18) ─ 
        BMI≥30 kg/m2 286 142(49.7)  2.2(1.7-2.7)  1.00(0.83-1.21) ─ 
        Unknown 1432 772(53.9)  1.5(1.4-1.7)  ─ ─ 
Self-reported HRT        
        Never user 692 329(47.5)  2.2(1.9-2.7)  1.00(reference) ─ 
        Past user 670 353(52.7)  2.0(1.7-2.2)  1.17(1.01-1.36) ─ 
        Current user 179 91(50.8)  1.8(1.3-2.4)  1.09(0.86-1.37) ─ 
        Unknown 1854 970(52.3)  1.7(1.5-1.9)  ─ ─ 
Family history of ovarian cancer         
        No 1112 557(50.1)  2.1(1.8-2.2)  1.00(reference) 1.00(reference) 
        Yes 94 62(66.0)  1.3(1.0-1.7)  1.56(1.20-2.02) 1.55(1.19-2.02) 
        Unknown 2189 1124(51.3)  1.8(1.6-2.0)  ─ ─ 
Family history of breast cancer        
        No 1551 766(49.4)  2.1(1.9-2.3)  1.00(reference) ─ 
        Yes 382 187(49.0)  2.1(1.8-2.5)  0.99(0.84-1.16) ─ 
        Unknown 1462 790(54.0)  1.5(1.4-1.7)  ─ ─ 
 
Abbreviation: BMI, body mass index; HRT, hormone replacement therapy. 
* Time to 25% discontinuation is the time at which 25% of the women discontinued their 
adjuvant hormone therapy. 
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†  
Variables were not included in the multivariable model if they were not significantly 
associated with discontinuation of adjuvant hormone therapy in the univariable models. 
‡ 
Pre-diagnosis symptom-relieving drugs and hormone replacement therapy were defined as 
filling at least one prescription of corresponding drugs one year before diagnosis of breast 
cancer.   
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Table 2. Early-treatment-stage (first-year) predictors for discontinuation of adjuvant hormone 
therapy in the following four years among 2 865 breast cancer patients. 
  Univariable   Multivariable 
 HR 95% CI P  HR 95% CI P 
Therapy type        
         Tamoxifen only 1.00 Reference   1.00 Reference  
        Aromatase inhibitor only 1.18 1.05 to 1.33 0.005  1.12 0.99 to 1.26 0.066
*
 
        Switching therapy 1.62 1.33 to 1.98 <.001  1.50 1.23 to 1.83 <.001
*
 
Symptom-relieving drugs        
    Analgesics        
            No 1.00 Reference   1.00 Reference  
            Yes 1.42 1.27 to 1.58 <.001  1.22 1.08 to 1.37 0.001
*
 
    Hypnotics and sedatives        
            No 1.00 Reference   1.00 Reference  
            Yes 1.43 1.27 to 1.61 <.001  1.21 1.07 to 1.37 0.003
*
 
    Antidepressant        
            No 1.00 Reference   1.00 Reference  
            Yes 1.42 1.24 to 1.62 <.001  1.22 1.06 to 1.40 0.007
*
 
    Gastrointestinal drugs        
            No 1.00 Reference   1.00 Reference  
            Yes 1.44 1.29 to 1.62 <.001  1.27 1.13 to 1.43 <.001
*
 
Number of symptom- 
relieving drugs 
       
            0 1.00 Reference   1.00 Reference  
            1 1.44 1.25 to 1.66 <.001  1.41 1.22 to 1.62 <.001
†
 
            2 1.57 1.34 to 1.83 <.001  1.54 1.31 to 1.80 <.001
†
 
            3 1.99 1.66 to 2.39 <.001  1.89 1.57 to 2.27 <.001
†
 
            4 2.55 1.96 to 3.31 <.001  2.41 1.85 to 3.14 <.001
†
 
 
Note: Patients discontinued or censored already during the first year of follow-up were 
excluded in these analyses. 
* 
Adjusting for age at diagnoses, Charlson comorbidity index, family history of ovarian cancer, 
and all variables listed in this table except for number of symptom-relieving drugs. 
† 
Adjusting for age at diagnoses, Charlson comorbidity index, family history of ovarian cancer, 
and therapy type. 
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Fig 1. 
 
  
Stockholm-Gotland Breast Cancer 
Register, 2001-2008 
 
Swedish Prescribed Drug Register 
July 1, 2005-August 31, 2013 
 
3 470 patients diagnosed with breast cancer between 2005 and 2008 in 
Stockholm, Sweden, who subsequently initiated adjuvant hormone therapy 
who initiated adjuvant hormone therapy  
1 652 patients: 
censored adjuvant therapy 
 during the follow-up 
 1 743 patients: 
discontinued adjuvant therapy 
during follow-up 
3 395 breast cancer patients for final analyses,  
after excluding 45 distant metastasis and 30 ER-negative breast cancer 
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Fig 2 
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Fig 3 
 
